Trump Unveils TrumpRx; Pfizer Agrees Discounts

President Trump unveiled TrumpRx, a government-run direct-to-consumer website scheduled to launch in early 2026 that he says will let Americans buy prescription medicines directly from manufacturers at steep discounts. Pfizer agreed to participate, offering select drugs — including Xeljanz and Eucrisa — at discounts reported to average roughly 50% and reach as high as 85%, and to extend most‑favored‑nation pricing to Medicaid. In return Pfizer pledged about $70 billion for U.S. research, development and manufacturing and reportedly secured a three‑year reprieve from the administration's threatened Section 232 tariffs on pharmaceuticals. The Oval Office announcement included Pfizer CEO Albert Bourla and prompted a rise in Pfizer shares, but many key terms remain confidential and details such as which other drugmakers will join and how insured patients will benefit are unclear. The administration framed TrumpRx as an effort to align U.S. drug prices with other wealthy countries and reduce federal Medicaid costs.